J
JUNTEN BIO
Developing new technologies in the field of regenerative medicine
About JUNTEN BIO
Junten Bio is a pioneering biotechnology company focused on the research and development of advanced cell therapies and diagnostic agents. The company primarily serves the healthcare sector, targeting medical institutions and research organizations involved in organ transplants. Operating in the biotechnology market, Junten Bio's business model revolves around developing and licensing novel cell therapies and antibody drugs designed to improve the success rates of organ transplants, including liver and kidney transplants. The company generates revenue through licensing agreements and partnerships with other pharmaceutical firms, such as its recent collaborations with AlliedCel Corporation and Sysmex Corporation. By leveraging cutting-edge research and strategic alliances, Junten Bio aims to contribute significantly to the global healthcare industry.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Tokyo, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- HHHU Holdings
FUJIFILM
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about JUNTEN BIO on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See JUNTEN BIO on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.